Related Experiment Video
Updated: May 12, 2026

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
Published on: August 15, 2019
BENTA disease or CARD11 gain-of-function? A novel variant with atypical features and a literature review
Letizia Baldini1, Bärbel Keller2, Lisa Dewitte3
1Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy; Dipartimento di Scienza della Sanità Pubblica e Pediatriche, Università degli Studi di Torino, Torino, Italy.
Insights
Gain-of-function mutations in the CARD11 gene cause BENTA disease. A novel CARD11 mutation presents atypically and highlights the risk of Hemophagocytic Lymphohistiocytosis (HLH) in these disorders.
Area of Science:
- Immunology
- Genetics
- Molecular Biology
Background:
- CARD11 (Caspase Recruitment Domain Family Member 11) is crucial for NF-κB signaling and immune cell function.
- Gain-of-function (GOF) mutations in CARD11 lead to BENTA disease, characterized by B-cell expansion, immune dysfunction, and infections.
Purpose of the Study:
- To describe a novel CARD11-GOF mutation (D357E) and its associated atypical BENTA phenotype.
- To expand the understanding of the clinical spectrum of CARD11-GOF disorders.
- To assess the prevalence of Hemophagocytic Lymphohistiocytosis (HLH) in CARD11-GOF mutations.
Main Methods:
- Clinical description of three patients with a novel CARD11-GOF mutation (D357E).
- In vitro functional analysis of the D357E variant's effect on NF-κB signaling.
- Systematic literature review of CARD11 GOF mutations using PubMed and EMBASE.
Main Results:
- The novel D357E variant activates NF-κB signaling in lymphocytes and HEK293T cells.
- Atypical BENTA phenotype observed, including high IgM and normal B-cell counts; one patient developed life-threatening HLH.
- Literature review of 29 patients revealed HLH as a common complication (18.8%), not always accompanied by B-lymphocytosis.
Conclusions:
- A novel pathogenic CARD11 variant expands the known clinical spectrum of CARD11 GOF disorders.
- Increased awareness of HLH risk is crucial for patients with CARD11 GOF mutations.
- The findings emphasize the variable clinical presentation of BENTA disease.
Introduction:
The CARD11 (Caspase Recruitment Domain Family Member 11) gene encodes a scaffold protein critical for NF-κB signaling, regulating B-cell differentiation and T-cell effector functions. Gain-of-function (GOF) mutations in CARD11 cause BENTA disease (B cell Expansion with NF-κB and T cell Anergy), an autosomal dominant disorder typically presenting with early-onset polyclonal B-cell lymphocytosis, splenomegaly, lymphadenopathy, and recurrent infections.
Methods:
We describe three related patients harboring a novel CARD11-GOF mutation (D357E), presenting with a BENTA phenotype with atypical features, including high IgM levels and a normal B-cell count, with life-threatening HLH in one case. Additionally, we conducted a systematic literature review using PubMed and EMBASE to identify previously reported cases of CARD11 GOF mutations.
Results:
In vitro functional analysis demonstrated that the D357E variant activates the NF-κB signaling pathway in primary lymphocytes and in HEK293T cells transfected with mutant CARD11. Our literature review identified 13 studies describing 29 patients. Notably, HLH emerged as a common complication of CARD11 GOF mutations (18.8 %), while B-lymphocytosis -though frequent- was not universally present.
Conclusion:
We identified a novel pathogenic CARD11 variant and described its atypical phenotype, further expanding the clinical spectrum of CARD11 GOF disorders. These findings underscore the need for increased awareness of HLH risk in patients with CARD11 GOF mutations.
Related Concept Videos
Pedigree Analysis
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Incomplete Dominance
Single Nucleotide Polymorphisms-SNPs
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Huntington Disease l: Introduction

